Telik's Proteasome Inhibitor Program Meets A Preclinical Development Milestone
�Telik, Inc.
(Nasdaq: TELK) announced that its novel small molecule proteasome
inhibitor program met a preclinical development milepost by demonstrating
anticancer activity in preclinical models of human leukemia. The proteasome
is an important cellular structure necessary for the growth and function of
cancer cells and suppression of the proteasome has been shown to advertize
cell cycle arrest and cancer cell death or apoptosis. Bortezomib, an
approved drug for the intervention of multiple myeloma, is based on this
mechanism. Telik's proteasome inhibitors are orally active, non-peptide,
non-boron based, and thus whitethorn lead to a drug candidate that might own
advantages over Bortezomib and other proteasome inhibitors.
"The potentially golden profile of these compounds was achieved
through the use of our TRAP(R) computational dose discovery applied science,"
said James Keck, Ph.D., Vice President of Biology at Telik. "We ar
currently conducting activities necessary to blue-ribbon a potency development
candidate."
Preliminary data on Telik's proteasome online pharmacy program was presented
at the 2008 annual confluence of the American Association for Cancer Research.
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on
discovering, developing and commercializing novel small molecule drugs to
treat life-threatening diseases. The company's to the highest degree advanced investigational drug
candidates in clinical development ar TELINTRA(R), a modified glutathione
analog for the treatment of cytopenias due to myelodysplastic syndrome or
chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the discussion
of modern ovarian crab and non-small cell lung cancer. Telik's product
candidates were ascertained using its proprietary drug discovery engineering,
TRAP, which enables the rapid and efficient discovery of pocket-size molecule
dose candidates. Additional information is available at
http://www.telik.com.
This press release contains "forward-looking" statements, including
statements regarding the potential qualities and capabilities of dose
candidates resulting from the small molecule proteasome inhibitor program
described above, including the potency ability of such drug candidates to
prevent or stop neoplasm cell division and starve tumors, and the potentiality
development of any dose candidate to treat genus Cancer. These forward-looking
statements are based upon Telik's flow expectations. There are important
factors that could drive Telik's results to differ materially from those
indicated by these forward-looking statements. Detailed info
regarding factors that crataegus laevigata cause actual results to differ materially from
the results expressed or implied by statements in this press vent may be
found in Telik's periodic filings with the Securities and Exchange
Commission, including the factors described in the surgical incision entitled "Risk
Factors" in its quarterly report on Form 10-Q for the quarter complete June
30, 2008. Telik does not undertake whatsoever obligation to update forward-looking
statements contained in this press release.
TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or
registered trademarks of Telik, Inc.
Telik, Inc.
http://www.telik.com
More info
(Nasdaq: TELK) announced that its novel small molecule proteasome
inhibitor program met a preclinical development milepost by demonstrating
anticancer activity in preclinical models of human leukemia. The proteasome
is an important cellular structure necessary for the growth and function of
cancer cells and suppression of the proteasome has been shown to advertize
cell cycle arrest and cancer cell death or apoptosis. Bortezomib, an
approved drug for the intervention of multiple myeloma, is based on this
mechanism. Telik's proteasome inhibitors are orally active, non-peptide,
non-boron based, and thus whitethorn lead to a drug candidate that might own
advantages over Bortezomib and other proteasome inhibitors.
"The potentially golden profile of these compounds was achieved
through the use of our TRAP(R) computational dose discovery applied science,"
said James Keck, Ph.D., Vice President of Biology at Telik. "We ar
currently conducting activities necessary to blue-ribbon a potency development
candidate."
Preliminary data on Telik's proteasome online pharmacy program was presented
at the 2008 annual confluence of the American Association for Cancer Research.
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on
discovering, developing and commercializing novel small molecule drugs to
treat life-threatening diseases. The company's to the highest degree advanced investigational drug
candidates in clinical development ar TELINTRA(R), a modified glutathione
analog for the treatment of cytopenias due to myelodysplastic syndrome or
chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the discussion
of modern ovarian crab and non-small cell lung cancer. Telik's product
candidates were ascertained using its proprietary drug discovery engineering,
TRAP, which enables the rapid and efficient discovery of pocket-size molecule
dose candidates. Additional information is available at
http://www.telik.com.
This press release contains "forward-looking" statements, including
statements regarding the potential qualities and capabilities of dose
candidates resulting from the small molecule proteasome inhibitor program
described above, including the potency ability of such drug candidates to
prevent or stop neoplasm cell division and starve tumors, and the potentiality
development of any dose candidate to treat genus Cancer. These forward-looking
statements are based upon Telik's flow expectations. There are important
factors that could drive Telik's results to differ materially from those
indicated by these forward-looking statements. Detailed info
regarding factors that crataegus laevigata cause actual results to differ materially from
the results expressed or implied by statements in this press vent may be
found in Telik's periodic filings with the Securities and Exchange
Commission, including the factors described in the surgical incision entitled "Risk
Factors" in its quarterly report on Form 10-Q for the quarter complete June
30, 2008. Telik does not undertake whatsoever obligation to update forward-looking
statements contained in this press release.
TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or
registered trademarks of Telik, Inc.
Telik, Inc.
http://www.telik.com
More info